DDInter1867 DDInter1000
A phenothiazine used as an antipsychotic agent and as an antiemetic.
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023.
Triflupromazine {u} (Compound) resembles {v} (Compound) Perphenazine
Perphenazine {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Perphenazine
Perphenazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivosidenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Clomipramine
Clomipramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivosidenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Promethazine
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivosidenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Pipotiazine
Pipotiazine {u} (Compound) resembles {v} (Compound) Methotrimeprazine
Methotrimeprazine {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Perphenazine
Perphenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Promazine
Promazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loperamide
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Desipramine
Desipramine {u} (Compound) resembles {v} (Compound) Promazine
Promazine {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Mequitazine
Mequitazine {u} (Compound) resembles {v} (Compound) Trifluoperazine
Trifluoperazine {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Triflupromazine {u} (Compound) resembles {v} (Compound) Thioridazine
Thioridazine {u} may lead to a major life threatening interaction when taken with {v} Sodium sulfate
Sodium sulfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Triflupromazine (Compound) resembles Perphenazine (Compound) and Perphenazine may lead to a major life threatening interaction when taken with Ivosidenib
Triflupromazine (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Triflupromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Triflupromazine (Compound) resembles Promethazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Triflupromazine (Compound) resembles Pipotiazine (Compound) and Pipotiazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may lead to a major life threatening interaction when taken with Ivosidenib
Triflupromazine (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Triflupromazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Triflupromazine (Compound) resembles Desipramine (Compound) and Desipramine (Compound) resembles Promazine (Compound) and Promazine may lead to a major life threatening interaction when taken with Ivosidenib
Triflupromazine (Compound) resembles Mequitazine (Compound) and Mequitazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may lead to a major life threatening interaction when taken with Ivosidenib
Triflupromazine (Compound) resembles Thioridazine (Compound) and Thioridazine may lead to a major life threatening interaction when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib